PIETRA, DANIELA
 Distribuzione geografica
Continente #
NA - Nord America 282
EU - Europa 207
AS - Asia 99
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 592
Nazione #
US - Stati Uniti d'America 269
IE - Irlanda 122
CN - Cina 98
DE - Germania 23
FI - Finlandia 23
IT - Italia 14
SE - Svezia 14
CA - Canada 13
GB - Regno Unito 5
NL - Olanda 3
MU - Mauritius 2
AU - Australia 1
CL - Cile 1
ES - Italia 1
IN - India 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 592
Città #
Dublin 122
Chandler 72
Beijing 37
New York 28
Ashburn 27
Helsinki 17
Lawrence 14
Princeton 14
Nanjing 13
Toronto 12
Shanghai 11
Wilmington 11
Medford 10
Nanchang 6
Hangzhou 5
Hebei 5
Jacksonville 5
Jiaxing 5
Changsha 4
Gallarate 4
Norwalk 4
Shenyang 4
Washington 4
Falls Church 3
Tianjin 3
Boardman 2
Dronten 2
Falkenstein 2
Jinan 2
Monmouth Junction 2
Rome 2
Seattle 2
Woodbridge 2
Berlin 1
Canberra 1
Fairfield 1
Fano 1
Fuzhou 1
Leawood 1
Milan 1
Modena 1
Montesilvano Marina 1
Ningbo 1
Pavia 1
Pune 1
San Francisco 1
Settimo Torinese 1
Totale 470
Nome #
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 64
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 52
Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculation 52
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 46
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 44
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 44
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 42
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 40
Diagnosis and management of prefibrotic myelofibrosis. 40
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 33
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms 33
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. 31
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. 30
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. 28
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. 26
Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications 10
Totale 615
Categoria #
all - tutte 2.787
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.787


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 0 1
2019/2020102 20 27 0 0 0 0 5 9 8 18 13 2
2020/202122 1 0 1 3 0 1 0 2 9 1 2 2
2021/202277 0 0 12 3 3 3 1 4 4 5 11 31
2022/2023248 26 16 6 8 15 19 0 17 130 3 7 1
2023/2024137 15 30 7 8 5 54 1 10 1 1 3 2
Totale 615